Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Asahi Kasei to Buy Veloxis for 143.2 Billion Yen, Eyes US Transplant Market
Asahi Kasei has agreed to acquire US-based Veloxis Pharmaceuticals Inc. for 143.2 billion yen, the Japanese conglomerate said on November 25, in a move aimed at entering the US transplant market by getting its hands on Envarsus XR (tacrolimus), an…
To read the full story
Related Article
- Asahi Kasei Aims for Pharma Sales of 150 Billion Yen by FY2025
October 6, 2021
- Asahi Kasei Completes Acquisition of Veloxis
March 5, 2020
- Asahi Kasei Closes Veloxis Acquisition
January 16, 2020
- Asahi Kasei Launches Tender Offer for Veloxis
December 16, 2019
BUSINESS
- Pfizer, ASKA to Co-Promote RSV Vaccine Abrysvo in Japan
March 9, 2026
- Towa Broadens Label for Tacrolimus in Cell Transplantation
March 9, 2026
- Japan Ethical Drug Sales Up 1.2% in January: Crecon
March 9, 2026
- Positive Price Revisions Seen at Several Firms in FY2026 Reform: Poll
March 6, 2026
- Japan Grants First-Ever Approval to iPSC-Based Therapies
March 6, 2026
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…